Slides
Page 1
1 Edit Title1
Page 2
2 2 Notice Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as “expects,” “reaffirms,” “intends,” “anticipates,” “plans,” “projects,” “believes,” “seeks,” “estimates,” “optimistic,” or variations of such words and similar expressions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ materially from AngioDynamics’ expectations, expressed or implied. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the scale and scope of the COVID-19 global pandemic, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, infringement of AngioDynamics’ technology or assertions that AngioDynamics’ technology infringes the technology of third parties, the ability of AngioDynamics to effectively compete against competitors that have substantially greater resources, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions (including inflation, labor shortages and supply chain challenges including the cost and availability of raw materials), the results of ongoing litigation, challenges with respect to third-party distributors or joint venture partners or collaborators, the results of sales efforts, the effects of product recalls and product liability claims, changes in key personnel, the ability of AngioDynamics to execute on strategic initiatives, the effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to obtain regulatory clearances or approval of its products, or to integrate acquired businesses, as well as the risk factors listed from time to time in AngioDynamics’ SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2024. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason.
Page 3
3 Edit Title3 Pursue Larger, Faster Growing Markets Significantly expanded the scope of our Med Tech portfolio through R&D, M&A, and clinical/regulatory initiatives by entering the mechanical thrombectomy market, capitalizing on the solid PAD market, and building on the under-penetrated prostate focal therapy market. Drive Portfolio Transformation Exited and/or divested certain non-strategic businesses, reallocating resources into differentiated technologies, an expanded and robust R&D pipeline, and investing in clinical data generation while exploring new indications to drive growth opportunities. Improve Financial Profile and Capital Structure Through strategic business development efforts, we recapitalized our balance sheet and transformed our portfolio to drive future margin expansion and sustained profitable growth. $3 B $10 B FY 2021 FY 2024 Med Tech Global TAM +233%
Page 4
4 4 Peripheral Artery Disease (PAD) $760M US TAM Venous Thromboembolism (VTE) $5.3B US TAM Prostate Care $2.7B Global TAM ($780M US) A leading medical technology company driving sustained growth and profitability through its commitment to expanding treatment options, enhancing patient outcomes, and improving quality of life, with a strategic focus on combating cardiovascular disease and cancer.
Page 5
5 To Become An innovative, versatile, hour - long prostate treatment *1,2 *Treatment time does not include patient prep, anesthesia initiation or recovery room time. 1-2 See reference page
Page 6
6 The First Non-Thermal, Radiation Free Ablation Technology • The only FDA cleared technology that uses electricity to destroy prostate tissue • Robust IP Portfolio Clinical Outcomes Patients and Physicians Need • Over 2,600 patients have been treated under protocol with 32 peer-reviewed studies • The only technology with an Ablate and Resect Trial Building Momentum and Strong Commercial Viability Proven Go-To Market Strategy For Developing New Markets • FDA clearance and CE Mark Approval for prostate tissue • IRE CPT 1 codes for prostate and liver approved 9/2024 and effective 01/2026 • Comprehensive clinical support, physician education, and patient awareness initiatives • Combined with one of the largest dedicated sales and clinical teams within our market 3 3 - See reference page REV 01 GL/ON/PR/3126
Page 7
7 *The NanoKnife System indications for use vary per region. Please refer to the indications for use for approved use per region
Page 8
8 The most diagnosed male cancer in 112 countries, including the U.S. annual diagnoses worldwide annual diagnoses in the U.S. Incidence projected to double by 2040 -The Lancet Commission on Prostate Cancer: Planning for the Surge in Cases “ The projected rise in prostate cancer cases cannot be prevented by lifestyle changes or public health interventions. Aging populations Increasing life expectancy Takes more healthy years from men’s lives than any other cancer 4 5 4 6 4-6 See reference page REV 01 GL/ON/PR/3126
Page 9
9 Radical surgery or external beam radiation therapy 7 8 9 †† † AngioDynamics Internal Estimates 7-9 See reference page REV 01 GL/ON/PR/3126
Page 10
10 Active Surveillance Definitive Treatment Possibility of cancer progression Risk of serious long term urological side effects 5 years 50.2% 10 years 38.7% 15 years 33.7% Of patients will avoid treatment, but this group will have more clinical progression, metastases, and androgen-deprivation therapy initiation when compared with patients who undergo definitive therapy Erectile Dysfunction Urinary Incontinence Baseline 34% 1-year 85% Erectile Dysfunction Urinary Incontinence Baseline 30% 1-year 71% Baseline 32% 1-year 62% Baseline 31% 1-year 39% Between Their Quality of Life or Controlling Their Cancer Low Risk Intermediate Risk High Risk Neoadjuvant ADT 30.2% 48.5% 79.1% Treatment Failure* 9.7% 22.7% 42.9% *at 8-year follow-up 10 11 12 12 13 10-13 See reference page REV 01 GL/ON/PR/3126
Page 11
11 Which aims to destroy the index lesion while preserving the natural anatomy, continence and erectile function 14 Advanced Imaging Patient Selection “Index Lesion” 11 Most lethal metastatic prostate cancers originate from a single cell within the ‘Index Lesion’ of the prostate. “ Active Surveillance Definitive Therapy Focal Therapy Accurate treatment of just the index lesion can control progression or recurrence of the disease.14 15 14-15 See reference page REV 01 GL/ON/PR/3126
Page 12
12 of diagnosed patients undergo a focal therapy each year ‘17 ‘18 ‘19 ‘20 ‘21 ‘22 ‘23 ‘24 ‘25 Focal Therapy (7,000) † AngioDynamics Internal Estimates † † † Potential Clinically Appropriate Patients REV 01 GL/ON/PR/3126
Page 13
13 Reproducible Results Learning Curve Time Constraints Today, focal therapy options are only ideal for a specific segment of the prostate. A piecemeal approach to focal therapy is prohibitive to broader physician adoption and limits patients’ access to care. Complex Integration Increased Costs Support & Staffing Cryo HiFu Brachy ? Other Technologies: • Transurethral Ultrasound • Water Vapor • Pressurized Water • Nano Particles • Microwave • Laser REV 01 GL/ON/PR/3126
Page 14
14 That Can Enable Broad Physician Adoption And Improved Care For Patients 1 2 3 1,2 1-3, 16-18 See reference page 1,16 1,3,17,18,19 REV 01 GL/ON/PR/3126
Page 15
15
Page 16
16 REV 01 GL/ON/PR/3126
Page 17
17 IRE selectively targets cell membranes Sufficient voltage permanently opens the ion channels of the cell Cell loses homeostasis leading to cell death 20 20 20 20 – See reference page REV 01 GL/ON/PR/3126
Page 18
18 And Aims to Preserve the Nerves, Urethra, and Urinary Sphincters 21,22 21,22 - See reference page REV 01 GL/ON/PR/3126
Page 19
19
Page 20
20 In Prostate Tissue Ablation *For detailed information, refer to the FDA's guidance document titled "Clinical Investigations for Prostate Tissue Ablation Devices." Regulatory Clarity Encourages Innovation Prioritizes Patient Safety The NanoKnife System with six outputs is indicated for surgical ablation of soft tissue. Indication before PRESERVE Trial International Prostate Data 32 publications 2,642 patients 1 2 *Clinical studies should establish a technologies ability to: 1,2 1,16 1,3,17,18,19 1-3. 16,19 See reference page REV 01 GL/ON/PR/3126
Page 21
21 Pivotal study of the NanoKnife System for ablation of prostate tissue in patients with intermediate-risk prostate cancer REV 01 GL/ON/PR/3126
Page 22
22 The PRESERVE Study Experience IRE IRE IRE IRE Apex 40.8% Base 15.0% Midline 44.2% Avg. Procedure Time 54.1 Minutes Avg. # of Electrodes 4.3 Avg. Procedure Time 54.1 Minutes Avg. # of Electrodes 4.3 Avg. Procedure Time 54.1 Minutes Avg. # of Electrodes 4.3 Mean Procedure Time 54.1 Minutes Mean # of Electrodes 4.3 *Treatment time does not include patient prep, anesthesia initiation or recovery room time. 1,2 – See reference page Anterior 41.7% Posterior 58.3% 1,2 REV 01 GL/ON/PR/3126
Page 23
23 The Treatment Utilizes Existing Imaging and Biopsy Skills NanoKnife Electrodes Prostate Bladder Transrectal Ultrasound Probe Grid Subjects 121 Clinical Sites 17 IRE-naïve Sites 14 The PRESERVE Study Experience Gleason 3+4 80.2% Gleason 4+3 19.8% Stepper 1,16 1,16 – See reference page REV 01 GL/ON/PR/3126
Page 24
24 IRE has the lowest impact on sexual function compared to Hifu and Cryo And provides strong ablation of targeted tissue A 2024 meta-analysis and systematic review of all primary studies reporting outcomes for focal therapy 23 *All IRE Data Collected Utilizing The NanoKnife System * 23 – See reference page REV 01 GL/ON/PR/3126
Page 25
25 U.S. Experience Confirms Strong International Data 1,16,17,18,19 *Data on file – Pivotal Study of the NanoKnife System for the Ablation of Prostate Tissue (PRESERVE) REV 01 GL/ON/PR/3126
Page 26
26 That Can Enable Broad Physician Adoption And Improved Care For Patients 1 2 3 • Not limited by gland size, tumor location, or calcifications • Able to ablate across the urethra, nerves, and urinary sphincters • Enables physicians to build expertise in a single technology • Typically, an hour procedure* • High level of experience with needle-based procedures • Uses existing imaging and biopsy skills • Reliable ablations with no skip lesions or heat sink • Increased margin expansion without negatively impacting erectile or urinary function • Does not restrict future treatment options 1,2 *Treatment time does not include patient prep, anesthesia initiation or recovery room time 1-3, 16-19 See reference page 1,16 1,3,17,18,19 REV 01 GL/ON/PR/3126
Page 27
27
Page 28
28 Capital Equipment Single-Use Disposable Electrodes (2-6 per procedure) Hardware Software Accessories Recurring Revenue REV 01 GL/ON/PR/3126
Page 29
29 1 Regulatory Approvals 2 Market Access Key Market Penetration Tactics *Based on potential procedures in countries with active NanoKnife users. 3 Strong Go-To Market Strategy REV 01 GL/ON/PR/3126
Page 30
30 The NanoKnife System is indicated for the ablation of prostate tissue in patients with intermediate risk prostate cancer. The NanoKnife System with six outputs is indicated for surgical ablation of soft tissue, including prostate tissue. 32 publications across 2,642 patients Pivotal Study of the NanoKnife System for the ablation of prostate tissue in patients with Intermediate-Risk Prostate Cancer REV 01 GL/ON/PR/3126
Page 31
31 • US Coverage: IRE included in the Medicare Fee Schedules for ASC and Hosp Outpatient settings effective 01/2021 • US Coding: IRE CPT 1 codes for prostate and for liver approved 9/2024 and effective 01/2026 • US Payment: APC 5362 – HOPPS 2025 national average payment $10,411 (+6% yoy) • Canada: WIRED Trial: Designed to be a prospective, non-randomized study in 100 subjects treated at up to 5 clinical sites. North America1 • United Kingdom: Institute for Health and Care Excellence (NICE) upgraded the use of the NanoKnife System to “Special Arrangements” allowing hospitals to start new services while collecting more data. PART Trial (RCT) comparing the effectiveness of partial prostate ablation vs radical prostatectomy across 800 patients. • Sweden: Prostate Cancer IRE Study (PRIS): A randomized controlled trial comparing focal therapy to radical treatment in localized prostate cancer – evaluating functional and oncological outcomes + an economic evaluation of each technique. • Netherlands: ENFORCE Trial – A Dutch government sponsored and funded RCT that includes the NanoKnife System for prostate treatment. Europe2 • China: Included in the Beijing medical insurance catalog: patients can be reimbursed 85% of the cost of the surgery and electrodes, effective from 10/20/24 Asia3 REV 01 GL/ON/PR/3126
Page 32
32 Direct Sales & Partnerships Patient Awareness Physician Education There is an increasing trend toward using the internet as the first source of health information compared to family/friends/coworkers, health care professionals, and traditional media. -US Health Information National Trends Survey “ Enhanced Customer Relationships Improved Product Utilization Market Agility Hands - on Training Master Course and Life Symposium REV 01 GL/ON/PR/3126 Physician Finder
Page 33
33 ‡ Internal AngioDynamics Data As of Q2 2024 Active Sites at the End of Q2 2024 Create a Strong Opportunity for Growth in the Future Active Physicians Active Facilities Care Site ASC 20% Private/Public 24% Academic Center 56% Physician Acquisition Procedural Adoption ‡ ‡ ‡ REV 01 GL/ON/PR/3126
Page 34
34 • Large and growing addressable market • Innovative, versatile, ~hour-long prostate treatment* • Addresses an unmet need for physicians, their facility, and their patients • Backed by strong clinical evidence • Upcoming Category 1 Payment effective 01/2026 • Strong revenue model built for growth • Commercial team capable of developing new markets through education *Treatment time does not include patient prep, anesthesia initiation or recovery room time REV 01 GL/ON/PR/3126
Page 35
35 1) Data on file - Pivotal Study of the NanoKnife System for the Ablation of Prostate Tissue (PRESERVE) 2) Scheltema, Matthijs J et al. “Impact on genitourinary function and quality of life following focal irreversible electroporation of different prostate segme nts.” Diagnostic and interventional radiology (Ankara, Turkey) vol. 24,5(2018): 268-275. doi:10.5152/dir.2018.17374 3) Van den Bos, W., et al. “Histopathological outcomes after irreversible electroporation for prostate cancer: Results of an ablate and Resect study. ” Journal of Urology, vol. 196, no. 2, Aug. 2016, pp. 552–559, https://doi.org/10.1016/j.juro.2016.02.2977. 4) The Lancet Commission on prostate cancer: planning for the surge in cases James, Nicholas D et al. The Lancet, Volume 403, Issue 10437, 1683 – 1722 5) Cancer in men: Prostate cancer is #1 for 118 countries globally. American Cancer Society. (2024, September 27). https://www.cancer.org/research/acs-research news/prostate-cancer- is-number-1-for-118-countriesworldwide.html#:~:text=An%20estimated%201.5%20million%20men,Norway%2C%20Sweden%2C%20and%20Barbados. 6) Global Burden of Disease 2019 Cancer Collaboration, Kocarnik JM, Compton K, et al. Cancer incidence, mortality, years of life lost, years lived with disability, and disability -adjusted life years for 29 cancer groups from 2010 to 2019: A systematic analysis for the Global Burden of Disease Study 2019 [Supplement]. JAMA Oncol. 2022;8(3):420-444. doi:10.1001/jamaoncol.2021.6987 7) Therapies for clinically localized prostate cancer | effective health care (EHC) program. (n.d.). https://effectivehealthcare.ahrq.gov/products/prostate-cancer-therapies-update/clinician 8) Klotz, Laurence. “Active surveillance and focal therapy for low-intermediate risk prostate cancer.” Translational andrology and urology vol. 4,3 (2015): 342-54. doi:10.3978/j.issn.2223- 4683.2015.06.03 9) Løvf, Marthe et al. “Multifocal Primary Prostate Cancer Exhibits High Degree of Genomic Heterogeneity.” European urology vol. 75,3 (2019): 498-505. doi:10.1016/j.eururo.2018.08.009 10) Kumar, Ravi et al. “The use of focal therapy for the treatment of prostate cancer in Canada: Where are we, how did we get here, and where are we going?.” Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 10.5489/cuaj.8888. 7 Oct. 2024, doi:10.5489/cuaj.8888 11) Timilshina, N et al. “Long-term Outcomes Following Active Surveillance of Low-grade Prostate Cancer: A Population-based Study Using a Landmark Approach.” The Journal of urology vol. 209,3 (2023): 540-548. doi:10.1097/JU.0000000000003097 12) Donovan JL, Hamdy FC, Lane JA, et al. Patient-Reported Outcomes 12 Years after Localized Prostate Cancer Treatment. Supplemental Table S1A-D [published correction appears in NEJM Evid. 2023 Jun;2(6):EVIDx2300122. doi:10.1056/EVIDx2300122]. NEJM Evid. 2023;2(4):EVIDoa2300018. doi:10.1056/EVIDoa2300018 13) Zumsteg, Z. S., Spratt, D. E., Romesser, P. B., Pei, X., Zhang, Z., Polkinghorn, W., McBride, S., Kollmeier, M., Yamada, Y., & Zelefsky, M. J. (2015). The natural history and predictors of outcome following biochemical relapse in the dose escalation era for prostate cancer patients undergoing definitive external beam radiotherapy. European Urology, 67(6), 1009–1016. https://doi.org/10.1016/j.eururo.2014.09.028 14) Bedi N, Reddy D, Ahmed HU. Targeting the cancer lesion, not the whole prostate. Transl Androl Urol. 2020 Jun;9(3):1518-1525. doi: 10.21037/tau.2019.09.12. PMID: 32676439; PMCID: PMC7354301. 15) Liu, Wennuan et al. “Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer.” Nature medicine vol. 15,5 (2009): 559-65. doi:10.1038/nm.1944 REV 01 GL/ON/PR/3126
Page 36
36 16) Cussenot O and Stricker P. Irreversible Electroporation for Patients with Localised Prostate Cancer: Expert Opinion on this Versatile Therapeutic Approach. EMJ Urol. 2021;9(1):56- 62. 17) Fainberg, Jonathan et al. “Targeted Ablation Using Ultrasound-Guided Irreversible Electroporation of Index Tumors (TARGET Study): Prospective Development Study Evaluating Safety, Patient-Reported Outcomes, and Oncologic Efficacy.” Urology practice, 101097UPJ0000000000000666. 17 Jul. 2024, doi:10.1097/UPJ.0000000000000666 18) Blazevski A, Scheltema MJ, Yuen B, et al. Oncological and quality-of-life outcomes following focal irreversible electroporation as primary treatment for localised prostate cancer: A biopsy-monitored prospective cohort. European Urology Oncology. 2020;3(3):283-290. doi:10.1016/j.euo.2019.04.008 19) De la Rosette, Jean et al. “A Multicenter, Randomized, Single-blind, 2-Arm Intervention Study Evaluating the Adverse Events and Quality of Life After Irreversible Electroporation for the Ablation of Localized Low-intermediate Risk Prostate Cancer.” The Journal of urology vol. 209,2 (2023): 347-353. doi:10.1097/JU.0000000000003051 20) Geboers, B., Scheffer, H. J., Graybill, P. M., Ruarus, A. H., Nieuwenhuizen, S., Puijk, R. S., van den Tol, P. M., Davalos, R. V., Rubinsky, B., de Gruijl, T. D., Miklavčič, D., & Meijerink, M. R. (2020). High-Voltage Electrical Pulses in Oncology: Irreversible Electroporation, Electrochemotherapy, Gene Electrotransfer, Electrofusion, and Electroimmunotherapy. Radiology, 295(2), 254–272. https://doi.org/10.1148/radiol.2020192190 21) Onik, Gary, et al. “Irreversible electroporation: Implications for prostate ablation.”Technology in Cancer Research & Treatment , vol. 6, no. 4, Aug. 2007, pp. 295–300, https://doi.org/10.1177/153303460700600405. 22) Blazevski, Alexandar, et al. “Focal ablation of apical prostate cancer lesions with irreversible electroporation (IRE).”World Journal of Urology, vol. 39, no. 4, 2 June 2020, pp. 1107– 1114, https://doi.org/10.1007/s00345-020-03275-z. 23) Tay, K.J., Fong, K.Y., Stabile, A. et al. Established focal therapy—HIFU, IRE, or cryotherapy—where are we now?—a systematic review and meta-analysis. Prostate Cancer Prostatic Dis (2024). https://doi.org/10.1038/s41391-024-00911-2 REV 01 GL/ON/PR/3126
Page 37
37 Statements: The NanoKnife System must be operated by properly qualified personnel only. Caution: Federal (USA) law restricts the use of the system by or on the order of a physician. Refer to Directions for Use and/or User Manual provided with the product for complete Instructions, Warnings, Precautions, Possible Adverse Effects and Contraindications prior to use of the product. Indications for Use US: The NanoKnife System with six outputs is indicated for surgical ablation of soft tissue, including prostate tissue. Canada: The NanoKnife System is a medical device for cell membrane electroporation. Electroporation is a phenomenon that occurs in cell membranes as cells are exposed to an electrical field of sufficiently high intensity. The electric field acts as a physicalstimulus, bringing about alterations in cell membranes that result in increased permeability. EU: The NanoKnife System is indicated for the ablation of prostate tissue in patients with intermediate risk prostate cancer. Contraindications: Ablation procedures using the NanoKnife System are contraindicated in the following cases: Ablation of lesions in the thoracic area in the presence of implanted cardiac pacemakers or defibrillators Ablation of lesions in the vicinity of implanted electronic devices or implanted devices with metal parts. Ablation of lesions of the eyes, including the eyelids. Patient history of Epilepsy or Cardiac Arrhythmia Recent history of Myocardial Infarction. Warnings: EU Only: The NanoKnife device has been evaluated for the ablation of prostate tissue in patients with intermediate risk prostate cancer. The use of this device in other organs for other disease states has not been fully evaluated. Clinical Issues (including Arrhythmia, Hypertension, and Thrombus Risks) Patients with Q-T intervals greater than 500 ms (milliseconds) are at an increased risk for inappropriate energy delivery and arrhythmia. Verification of proper function of a synchronization device before initiating energy delivery is essential in these patients. Asynchronous energy delivery (90 PPM (Pulses Per Minute)) might trigger atrial or ventricular fibrillation, especially in patients with structural heart disease. Ensure that proper interventions (e.g. defibrillator) and appropriately trained personnel are readily available for dealing with potential cardiac arrhythmias. Using QRS synchronization devices whose output is not compatible with the specifications listed in this manual may result in arrhythmias including ventricular fibrillation. Adequate precautions should be taken for patients with implantable electrical devices. Note the contraindication in certain patients. There are potential risks associated with the location of the ablation: near the pericardium (tachycardia), or near the vagus nerve (bradycardia). Additional patients may be at risk with insufficient muscle blockade or anesthetic analgesia (reflex tachycardia and reflex hypertension); patients with abnormal sinus rhythm prior to an ablation (arrhythmia); patients with a history of hypertension (hypertension); or patients with partial portal venous thrombosis, low central venous pressure (CVP), and a prothrombotic condition (venous thrombosis). Use of Electrodes: Avoid repeated vascular insult during electrode placement. As anticipated with a needle-related procedure, repeated vascular insult due to multiple insertions into a vessel by an electrode during electrode placement may cause thrombus. Ensure continuous image guidance during the needle placements. Failure to do so can lead to traumatic injury to surrounding structures. Care should be taken during electrode placement in areas that require tissue be separated or retracted to avoid surrounding tissue damage. To avoid risks of infection, always maintain the electrodes’ protective packaging (cap, tubes, etc.) when the electrodes are not placed in the patient. Only electrode probes with intact electrical insulation must be used. Any electrodes with damaged electrical insulation must be discarded immediately and not connected to the NanoKnife Generator. To preserve the electrode’s sterility do not remove the electrodes from the packaging until the User is ready to apply the electrode to the patient. Do not use the electrodes after the expiration date printed on their packaging. Observe the electrodes manufacturer’s specific instructions (e.g., printed on the electrodes’ packaging). Only use AngioDynamics Electrode Probes with the NanoKnife System Generator. Maintain electrical separation of the electrodes from safety ground by doing the following Disconnect any electrode from the Generator that is not applied to the patient. Avoid any clamping of the electrode’s cable, unless explicitly instructed or authorized by the electrode’s manufacturer. Do not connect any devices (e.g., measurement) to the electrodes unless they have been supplied by and specifically indicatedfor such a use by the manufacturer. REV 01 GL/ON/PR/3126
Page 38
38 Use of Generator (including Electrocution Hazard) No modification of this equipment is allowed. To avoid risk of electric shock, this equipment must only be connected to a supply mains with protective earth. The Generator internally produces voltages that are dangerous and may be fatal. The Generator does not contain parts serviceable by the User, and should not be opened. Do not use the Generator in the presence of flammable or explosive gas mixtures. For electrical safety, the Generator needs grounding. Use only medical grade main power supply cords, e.g., those supplied by the manufacturer. Before plugging the Generator to the main, ensure that the main power cords are not damaged. Replace them if any damage is noticed – main cords cannot be repaired. Do not connect or disconnect the Generator from the main power cord with wet hands. Confirm that the main power cord will be connected to a properly grounded electrical outlet. Whenever necessary, replace Generator fuses only with fuses specified in this manual. Maintenance should be carried out only by trained personnel. The Generator must undergo periodic preventative maintenance as specified in the Maintenance and Service. The NanoKnife User Manual is a fundamental part of the Generator and should always accompany it. Users must refer to this manual for correct and complete information on the use of the Generator. Potential Adverse Effects (Rest of world): Adverse effects that may be associated with the use of the NanoKnife system include, but are not limited to the following: Arrhythmia Atrial fibrillation or flutter Bigeminy Bradycardia Heart block or atrioventricular block Paroxysmal supraventricular tachycardia Tachycardia Reflex tachycardia Ventricular tachycardia Ventricular fibrillation Damage to critical anatomical structure (nerve, vessel, and/or duct) Dysuria Epididymitis Erectile Dysfunction Fistula formation Haematuria Hematoma Hemorrhage Hemothorax Infection Pneumothorax Prostatitis Reflex Hypertension Unintended mechanical perforation Urethral sludge Urethral stricture Urinary incontinence Urinary retention Urosepsis Vagal Stimulation, asystole Venous Thrombosis Potential Adverse Effects (US) Adverse effects that may be associated with the use of the NanoKnife system include, but are not limited to the following: • Abdominal Pain • Arrhythmia o Atrial fibrillation or flutter o Bigeminy o Bradycardia o Heart block or atrioventricular block o Paroxysmal supraventricular tachycardia ▪ Reflex tachycardia ▪ Ventricular tachycardia o Ventricular fibrillation • Bladder spasm • Damage to critical anatomical structure (nerve, vessel, and/or duct) • Fistula Formation • Hematoma • Hemorrhage • Hemothorax • Infection • Pneumothorax • Reflex Hypertension • Unintended mechanical perforation • Urinary retention • Vagal stimulation, asystole • Venous thrombosis REV 01 GL/ON/PR/3126 AngioDynamics, the AngioDynamics logo, NanoKnife, and the NanoKnife logo are trademarks and/or registered trademarks of AngioDynamics, Inc., an affiliate or subsidiary. (C) 2024 AngioDynamics, Inc.